Cevimeline hydrochloride hemihydrate
CAS : 153504-70-2
Ref. 3D-FC150175
1mg | Arrêté | ||
2mg | Arrêté | ||
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté |
Informations sur le produit
- CevimelineHCl
- C07772
- Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, hydrochloride, hydrate (2:1), cis-
- Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, hydrochloride, hydrate (2:2:1), (2'R,3R)-rel-
- (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] hydrochloride hydrate (2:2:1)
- (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] hydrochloride (1:1)
Cevimeline hydrochloride hemihydrate is a cholinergic agent that is used to treat dry mouth. It activates muscarinic receptors in the salivary gland, leading to increased salivation. Cevimeline hydrochloride hemihydrate has been shown to be well tolerated in clinical trials and does not have significant side-effects. There is some evidence for its efficacy in reducing disease activity in geriatric patients with Sjögren's syndrome, although this has not been demonstrated statistically.